☆ 4.7 Meeting Abstract

Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: A phase I/IIa study.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 36, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2018.36.15_suppl.10504

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma

Rebecca Ronsley, Celine D. Hounjet, Sylvia Cheng, Shahrad Rod Rassekh, Walter J. Duncan, Christopher Dunham, Jane Gardiner, Arvindera Ghag, Jeffrey P. Ludemann, David Wensley, Wingfield Rehmus, Michael A. Sargent, Juliette Hukin

Summary: Six NF-1 patients were treated with trametinib, showing either partial response or stability in all cases, with generally well-tolerated adverse effects of grade 1-2 paronychia or dermatitis. Further data and clinical trials are needed to assess the efficacy and durability of this treatment method.

CANCER MEDICINE (2021)

Add to Collection

Review Clinical Neurology

Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review

Ike Iheanacho, Hyun Kyoo Yoo, Xiaoqin Yang, Sophie Dodman, Rachel Hughes, Suvina Amin

Summary: The purpose of the study is to investigate the epidemiology, burden of illness, and outcomes of surgical resection in pediatric patients with NF-1 and associated PNs. The results suggest that NF-1 is rare in children, but has increased morbidity and mortality in those with associated PNs. Surgical outcomes for PNs are often poor, indicating significant unmet needs in these patients.

NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Oncology

Management of neurofibromatosis type 1-associated plexiform neurofibromas

Michael J. Fisher, Jaishri O. Blakeley, Brian D. Weiss, Eva Dombi, Shivani Ahlawat, Srivandana Akshintala, Allan J. Belzberg, Miriam Bornhorst, Miriam A. Bredella, Wenli Cai, Rosalie E. Ferner, Andrea M. Gross, Gordon J. Harris, Robert Listernick, Ina Ly, Staci Martin, Victor F. Mautner, Johannes M. Salamon, Kilian E. Salerno, Robert J. Spinner, Verena Staedtke, Nicole J. Ullrich, Meena Upadhyaya, Pamela L. Wolters, Kaleb Yohay, Brigitte C. Widemann

Summary: Plexiform neurofibromas are a common manifestation of neurofibromatosis type 1, with surgery being the main treatment option in the past. However, recent regulatory approvals of the MEK inhibitor selumetinib have provided new options for PN management. Currently, there is no consensus on the definition, diagnostic evaluation, surveillance strategy, and treatment indications for PN. This review provides consensus recommendations from NF1 experts to address these questions.

NEURO-ONCOLOGY (2022)

Add to Collection

Article Clinical Neurology

RNA-sequencing highlights differential regulated pathways involved in cell cycle and inflammation in orbitofacial neurofibromas

Eddie Luidy Imada, Diego Strianese, Deepak P. Edward, Rawan AlThaqib, Antionette Price, Antje Arnold, Hailah Al-Hussain, Luigi Marchionni, Fausto J. Rodriguez

Summary: The study identified gene expression differences between orbitofacial NFs and NFs occurring at other locations, suggesting that orbitofacial NFs may have higher local aggressiveness and treatment challenges. Further investigation may be warranted given the disproportionate morbidity associated with orbitofacial NFs.

BRAIN PATHOLOGY (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Congenital Craniofacial Plexiform Neurofibroma in Neurofibromatosis Type 1

Antonella Cacchione, Alessia Carboni, Mariachiara Lodi, Rita De Vito, Andrea Carai, Antonio Marrazzo, Marina Macchiaiolo, Ioan Paul Voicu, Angela Mastronuzzi, Giovanna Stefania Colafati

Summary: Different radiographical imaging modalities were used to diagnose and evaluate the condition of a patient with NF1 and PN, biopsy confirmed the diagnosis. NF1 diagnosis at birth remains challenging, with congenital PN recognized in 20% of cases. Early detection of PN progression allowed for necessary life-saving interventions.

DIAGNOSTICS (2021)

Add to Collection

Review Chemistry, Medicinal

Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis

Dun Wang, Lingling Ge, Zizhen Guo, Yuehua Li, Beiyao Zhu, Wei Wang, Chengjiang Wei, Qingfeng Li, Zhichao Wang

Summary: This meta-analysis evaluated the effectiveness and safety of trametinib in treating NF1-related nerve tumors. The results showed that trametinib had a satisfactory ability to stabilize tumor progression but a more limited ability to shrink tumors. The safety profile of trametinib was satisfactory.

PHARMACEUTICALS (2022)

Add to Collection

Article Clinical Neurology

Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1

Helen Toledano, Gad Dotan, Rivka Friedland, Rony Cohen, Iftach Yassur, Hagit Toledano-Alhadef, Shlomi Constantini, Mika Shapira Rootman

Summary: Trametinib can reduce tumor size in some young children with orbital PNF and may prevent progressive disfigurement. The dosages are adjusted for children of different ages, with no changes in visual function observed during treatment, but some children experienced skin and nail toxicities of grades 1-2.

CHILDS NERVOUS SYSTEM (2021)

Add to Collection

Article Health Care Sciences & Services

The Number of Surgical Interventions and Specialists Involved in the Management of Patients with Neurofibromatosis Type I: A 25-Year Analysis

Chih-Kai Hsu, Rafael Denadai, Chun-Shin Chang, Chuan-Fong Yao, Ying-An Chen, Pang-Yun Chou, Lun-Jou Lo, Yu-Ray Chen

Summary: This study presents a 25-year experience of utilizing a comprehensive multidisciplinary team-based surgical approach for treating NF-1 patients at a single institution. The study highlights the potential benefits of such an approach in providing comprehensive individualized care, reducing the number of surgical interventions and involvement of specialists.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Article Oncology

Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Morphological and Immunohistochemical Study

Reinhard E. Friedrich, Louisa K. N. Noernberg, Christian Hagel

Summary: This study aimed to characterize the growth pattern and antigen profile of peripheral nerve sheath tumors (PNST) in patients with Neurofibromatosis type 1 (NF1), with a focus on the morphological characteristics of diffuse plexiform neurofibroma (DPNF). The study found distinct cellular characteristics and differences in antigen expression among different types of PNST. The findings provide insight into the biological differences between these tumors.

ANTICANCER RESEARCH (2022)

Add to Collection

Review Oncology

Dermatologic Manifestations of Neurofibromatosis Type 1 and Emerging Treatments

Dina Poplausky, Jade N. N. Young, Hansen Tai, Ryan Rivera-Oyola, Nicholas Gulati, Rebecca M. M. Brown

Summary: Neurofibromatosis type 1 (NF1) is a genetic neuroectodermal disorder associated with various skin findings, including cutaneous neurofibromas. There are limited treatment options for the cutaneous manifestations of NF1, and interdisciplinary collaboration is often necessary for the appropriate care of these patients. Increased awareness of NF1 and its dermatologic associations is important for providing adequate care to patients.

CANCERS (2023)

Add to Collection

Article Dermatology

Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor

Eran Cohen-Barak, Hagit Toledano-Alhadef, Nada Danial-Farran, Ido Livneh, Banan Mwassi, Maysa Hriesh, Fadia Zagairy, Chen Gafni-Amsalem, Husam Bashir, Morad Khayat, Nassim Warrour, Osnat Sher, Daphna Marom, Sergey Postovsky, Tal Dujovny, Michael Ziv, Stavit A. Shalev

Summary: The study identified germline mutations in NF1 and LZTR1 genes, as well as a somatic variant in GNAZ, in a 9-month-old NF1 patient with life-threatening plexiform neurofibroma. Cellular analysis revealed increased ERK 1/2 activation in cells expressing mutant GNAZ, suggesting a synergistic effect of NF1, LZRT1, and GNAZ variants contributing to the severity of the patient's condition. Treatment with the MEK inhibitor trametinib resulted in significant clinical improvement, supporting the use of targeted therapy based on individual genetic variations.

EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Article Oncology

Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study

Chelsea Kotch, Kristina Wagner, J. Harris Broad, Eva Dombi, Jane E. E. Minturn, Peter Phillips, Katherine Smith, Yimei Li, Ian N. N. Jacobs, Lisa M. M. Elden, Michael J. J. Fisher, Jean Belasco

Summary: The study evaluated the efficacy of vinblastine and methotrexate in NF1-associated plexiform neurofibroma. The results showed that this treatment was effective in some patients, but 2D imaging was not sensitive enough for evaluating tumor volume.

CANCERS (2023)

Add to Collection

Article Medicine, General & Internal

Surgical Treatment and Complications of Deep-Seated Nodular Plexiform Neurofibromas Associated with Neurofibromatosis Type 1

Kunihiro Ikuta, Yoshihiro Nishida, Tomohisa Sakai, Hiroshi Koike, Kan Ito, Hiroshi Urakawa, Shiro Imagama

Summary: This study retrospectively reviewed surgical excision cases of deep-seated nodular plexiform neurofibromas in patients with neurofibromatosis type 1 and found that surgical treatment of these tumors is relatively safe with improvement in preoperative symptoms.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Oncology

Neurofibroma Development in Neurofibromatosis Type 1: Insights from Cellular Origin and Schwann Cell Lineage Development

Ling-Ling Ge, Ming-Yan Xing, Hai-Bing Zhang, Zhi-Chao Wang

Summary: This review summarizes the accumulating evidence on the cellular and molecular pathogenesis of neurofibroma development. Neurofibromatosis type 1 (NF1) is a genetic tumor predisposition syndrome that affects about 1 in 3000 newborns and is caused by mutations in the NF1 gene. The distinct characteristics of plexiform and cutaneous neurofibromas have prompted hypotheses about the origin and developmental features of these tumors.

CANCERS (2022)

Add to Collection

Article Behavioral Sciences

Epidemiological profile and clinical characteristics of 491 Brazilian patients with neurofibromatosis type 1

Luiz Guilherme Darrigo Junior, Victor Evangelista de Faria Ferraz, Marina Candido Visontai Cormedi, Luissa Hikari Hayashi Araujo, Mariana Prado Silva Magalhaes, Rafaella Curis Carneiro, Luis Henrique Nunes Sales, Mendel Suchmacher, Karin Soares Cunha, Aguinaldo Bonalumi Filho, David Rubem Azulay, Mauro Geller

Summary: Neurofibromatosis type 1 (NF1) is a common genetic and sporadic disease, and plexiform neurofibroma (PN) is a significant complication. This study retrospectively analyzed 491 NF1 patients in two reference centers in Brazil, and found that approximately 38% of patients had PN, mainly affecting the head and neck and extremities. The study also found that PN can significantly reduce patients' life quality and some patients may develop malignant peripheral nerve sheath tumors.

BRAIN AND BEHAVIOR (2022)

Add to Collection

Article Oncology

Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma

Pascale Varlet, Eric Bouffet, Michela Casanova, Felice Giangaspero, Manila Antonelli, Darren Hargrave, Ruth Ladenstein, Andy Pearson, Cynthia Hawkins, Fatima Barbara Koenig, Josef Rueschoff, Christian Schmauch, Claudia Buehnemann, Pilar Garin-Chesa, Norbert Schweifer, Martina Uttenreuther-Fischer, Neil Gibson, Carina Ittrich, Nicole Kraemer, Flavio Solca, Britta Stolze, Birgit Geoerger

Summary: The study found that high levels of ErbB receptor expression have heterogeneous distribution in most tumor types, and overexpression and/or amplification of EGFR/HER2 may serve as potential enrichment biomarkers for clinical trials of ErbB-targeted drugs.

PEDIATRIC BLOOD & CANCER (2022)

Add to Collection

Article Genetics & Heredity

Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019

Yoshua Colyn Collins-Sawaragi, Rosalie Ferner, Grace Vassallo, Germana De Agro, Simon Eccles, Jill Cadwgan, Darren Hargrave, Eileen Hupton, Judith Eelloo, Lauren Lunt, Vivian Tang, Emma Burkitt Wright, Karine Lascelles

Summary: This study provides an overview of the location, symptoms, and management of plexiform neurofibroma (PN) in children with Neurofibromatosis Type 1 (NF1) attending two national specialized services. The study found that PN primarily occurs in craniofacial and limb areas, with a significant proportion of patients experiencing disfigurement, pain, and impairment of function. The majority of patients were managed either conservatively or through surgical intervention, with a small percentage receiving MEK inhibitor therapy.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2022)

Add to Collection

Article Oncology

A 40-Year Cohort Study of Evolving Hypothalamic Dysfunction in Infants and Young Children (<3 years) with Optic Pathway Gliomas

Stefania Picariello, Manuela Cerbone, Felice D'Arco, Hoong-Wei Gan, Patricia O'Hare, Kristian Aquilina, Enrico Opocher, Darren Hargrave, Helen A. Spoudeas

Summary: Young children with optic pathway tumours are at risk of developing serious health issues affecting hormone, metabolic, and neurobehavioral functions. Factors such as tumor position, recurrence, treatment, age at diagnosis, and involvement of the hypothalamus contribute to the risk of complex health issues in these patients. Understanding the impact of tumor-induced midbrain injury and providing timely support for neurobehavioral and hormonal needs is crucial to improve the quality of life for survivors and their families.

CANCERS (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

Arnoldo Piccardo, Nathalie L. Albert, Lise Borgwardt, Frederic H. Fahey, Darren Hargrave, Norbert Galldiks, Nina Jehanno, Lars Kurch, Ian Law, Ruth Lim, Egesta Lopci, Lisbeth Marner, Giovanni Morana, Tina Young Poussaint, Victor J. Seghers, Barry L. Shulkin, Katherine E. Warren, Tatjana Traub-Weidinger, Pietro Zucchetta

Summary: This document provides guidelines for the use of [F-18]FDG and radiolabelled amino acid PET imaging in pediatric patients with brain gliomas. The recommendations are consensus opinions of experienced leaders in the field and further research is needed to support evidence-based recommendations.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Article Ophthalmology

Visual outcomes and predictors in optic pathway glioma: a single centre study

R. Bowman, B. Walters, V Smith, K. L. Prise, S. E. Handley, K. Green, K. Mankad, P. O'Hare, C. Dahl, M. Jorgensen, E. Opocher, D. Hargrave, D. A. Thompson

Summary: The study found that retinal nerve fiber layer thickness on OCT and VEP were useful in predicting future visual acuity and vision, as well as in planning treatment. A high prevalence of homonymous hemianopia was observed in the study.

EYE (2023)

Add to Collection

Article Oncology

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma

Eric Bouffet, Birgit Geoerger, Christopher Moertel, James A. Whitlock, Isabelle Aerts, Darren Hargrave, Lisa Osterloh, Eugene Tan, Jeea Choi, Mark Russo, Elizabeth Fox

Summary: This study establishes pediatric dosing and pharmacokinetics, as well as efficacy and safety, of trametinib with or without dabrafenib in children with BRAF V600-mutant LGG. The recommended phase II dose of trametinib, with or without dabrafenib, was determined as 0.032 mg/kg or 0.025 mg/kg. Both monotherapy and combination therapy showed efficacy and tolerability in treating BRAF V600-mutant LGG.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

A novel diagnostic method for a rare fungus: FcMBL facilitates Wickerhamomyces anomalus identification in an immunocompromised neonate

Conor J. Higgins, Kerry-Anne Kite, Nigel Klein, Michael Super, Michael T. Mccurdy, Darren Hargrave

Summary: Fungemia has a negative impact on patient outcomes, but current diagnostic methods lack sensitivity in identifying emerging rare fungal infections. This study reports a case of Wickerhamomyces anomalus infection in an immunocompromised neonate, where FcMBL bead-based matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) identified the species approximately 30 hours before standard pathogen identification methods. The use of FcMBL bead-based MALDI-TOF MS may improve the speed and accuracy of identifying rare pathogens, leading to more effective treatment.

MEDICAL MYCOLOGY CASE REPORTS (2023)

Add to Collection

Meeting Abstract Oncology

Dabrafenib plus trametinib (dab plus tram) in relapsed/refractory (r/r) BRAF V600-mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial.

Darren R. Hargrave, Keita Terashima, Junichi Hara, Uwe R. Kordes, Santhosh A. Upadhyaya, Felix Sahm, Eric Bouffet, Roger J. Packer, Olaf Witt, Lali Sandalic, Agnieszka Kieloch, Mark W. Russo, Kenneth J. Cohen

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1-negative tumors.

Susan N. Chi, Franck Bourdeaut, Michela Casanova, Lindsay Baker Kilburn, Darren R. Hargrave, Geoffrey Brian McCowage, Navin R. Pinto, Jay Yang, Raminder Chadha, Bhaskar Kahali, Coya Tapia, Karsten Nysom

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

THE EFFICACY OF FIBRE AND PREBIOTIC INTERVENTIONS ON CLINICAL OUTCOMES IN CANCER AND HAEMATOPOIETIC STEM CELL THERAPIES: SYSTEMATIC LITERATURE REVIEW

Breeana Gardiner, Hannah Wardill, Graeme O'Connor, Darren Hargrave, Gary Frost, Aaron Lett

PEDIATRIC BLOOD & CANCER (2022)

Add to Collection

Article Oncology

Pediatric high-grade gliomas and the WHO CNS Tumor Classification-Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates

Gerrit H. Gielen, Joshua N. Baugh, Dannis G. van Vuurden, Sophie E. M. Veldhuijzen van Zanten, Darren Hargrave, Maura Massimino, Veronica Biassoni, Andres Morales la Madrid, Michael Karremann, Maria Wiese, Ulrich Thomale, Geert O. Janssens, Andre O. von Bueren, Thomas Perwein, Gunther Nussbaumer, Eelco W. Hoving, Pitt Niehusmann, Marco Gessi, Robert Kwiecien, Simon Bailey, Torsten Pietsch, Felipe Andreiuolo, Christof M. Kramm

Summary: This study investigated the impact of the WHO classification on pediatric high-grade gliomas. It found differences between neuro-oncologists and neuropathologists in their perception of molecularly defined tumor types and the changes made in the classification. While improvements were perceived in the 2021 edition, there are still relevant issues that need to be addressed, emphasizing the need for collaboration between pathologists and oncologists.

NEURO-ONCOLOGY ADVANCES (2022)

Add to Collection

Article Health Care Sciences & Services

Multimorbidity patterns and risk of hospitalisation in children: A population cohort study of 3.6 million children in England, with illustrative examples from childhood cancer survivors

Sheng-Chia Chung, Stefanie Mueller, Katherine Green, Wai Hoong Chang, Darren Hargrave, Alvina G. Lai

Summary: This study characterized the morbidity patterns in children and compared them between childhood cancer survivors and children without cancer. The findings demonstrate that childhood cancer survivors have a higher prevalence and subsequent risk of hospitalization for various morbidities.

LANCET REGIONAL HEALTH-EUROPE (2022)

Add to Collection

Review Oncology

Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group

Giovanni Morana, Dennis Shaw, Shannon M. MacDonald, Claire Alapetite, Thankamma Ajithkumar, Aashim Bhatia, Herve Brisse, Camilo Jaimes, Thomas Czech, Girish Dhall, Jason Fangusaro, Cecile Faure-Conter, Maryam Fouladi, Darren Hargrave, Julie H. Harreld, Dipayan Mitra, James C. Nicholson, Mark Souweidane, Beate Timmermann, Gabriele Calaminus, Ute Bartels, Brigitte Bison, Matthew J. Murray

Summary: Homogeneous and common objective disease assessments and standardised response criteria are essential for international clinical trials on CNS germ cell tumours. The current differences between European protocols and those of North America regarding radiological disease response assessment prompted the establishment of an international working group. This group developed new clinical imaging standards for the most common sites of CNS germ cell tumours, allowing for a more consistent evaluation of treatment response and facilitating comparison of treatment outcomes across international studies.

LANCET ONCOLOGY (2022)

Add to Collection

Meeting Abstract Clinical Neurology

DNA methylation machine learning and radiological features predict molecular classification of glioneuronal tumours

T. Stone, K. Mankad, A. Tan, W. Jan, J. Pickles, M. Gogou, J. Chalker, M. Kristiansen, T. Mistry, O. Ogunbiyi, S. Ahmed, H. Cross, M. Hubank, D. Hargrave, T. Jacques

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2022)

Add to Collection

Article Oncology

DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

Elisa Izquierdo, Diana M. Carvalho, Alan Mackay, Sara Temelso, Jessica K. R. Boult, Giulia Pericoli, Elisabet Fernandez, Molina Das, Valeria Molinari, Yura Grabovska, Rebecca F. Rogers, Maria Antonietta Ajmone-Cat, Paula Z. Proszek, Mark Stubbs, Sarita Depani, Patricia O'Hare, Lu Yu, Georgia Roumelioti, Jyoti S. Choudhary, Matthew Clarke, Amy R. Fairchild, Thomas S. Jacques, Richard G. Grundy, Lisa Howell, Susan Picton, Jenny Adamski, Shaun Wilson, Juliet C. Gray, Bassel Zebian, Lynley Marshall, Fernando Carceller, Jacques Grill, Maria Vinci, Simon P. Robinson, Michael Hubank, Darren Hargrave, Chris Jones

Summary: The MAPK pathway is a therapeutic target in DIPG, and combination therapy with trametinib and dasatinib may overcome single-agent resistance.

CANCER DISCOVERY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.